Cited by 208Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and DiagnosticsPlatelet Disorders and Treatments

The DOI matches its Crossref record.

Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients

Open access

Sibbing, Dirk, Steinhubl, Steven R., Schulz, Stefanie, Schömig, Albert, Kastrati, Adnan·2010·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2010.03.048

Open this paper in CoChat — free account Open PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2010.03.048

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No references could be resolved yet.

Research works printed but not linked: 5

Angiolillo, 2007, Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives, J Am Coll Cardiol, 49, 1505, 10.1016/j.jacc.2006.11.044 · DOI
Sibbing, 2010, Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement, J Thromb Haemost, 8, 250, 10.1111/j.1538-7836.2009.03709.x · DOI
Doyle, 2009, Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice, J Am Coll Cardiol, 53, 2019, 10.1016/j.jacc.2008.12.073 · DOI
Azar, 1996, Optimal intensity of oral anticoagulant therapy after myocardial infarction, J Am Coll Cardiol, 27, 1349, 10.1016/0735-1097(96)00020-4 · DOI
Sibbing, 2009, Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis, J Am Coll Cardiol, 53, 849, 10.1016/j.jacc.2008.11.030 · DOI

Sorted by citations

Items 101–190 of 190

Clopidogrel 150 vs. 75 mg day−1 in patients undergoing percutaneous coronary intervention: a meta‐analysis
Hao, P., ZHANG, M. X., LI, R. J., YANG, J. M., Wang, J. L., CHEN, Y. G., & ZHANG, Y. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04216.x · Cited by 12
What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?
Cohen, M. V., & Downey, J. M. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419882923 · Cited by 12
Meta-analysis of Comparison of the Newer P2Y12 Inhibitors (Oral Preparation or Intravenous) to Clopidogrel in Patients With Acute Coronary Syndrome
Zhang, L., Lü, J., Dong, W., Tian, H., Feng, W., You, H., He, H., Ma, J., & Dong, Y. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000451 · Cited by 10
Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial.
Gladding, P., Panattoni, L., Webster, M., Cho, L., & Ellis, S. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.08.012 · Cited by 11
Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis
Selhorst, G., Schmidtler, F., Ott, A., Hitzke, E., Tomelden, J., Antoni, D., Hoffmann, E., & Rieber, J. (2019) · Platelets · doi:10.1080/09537104.2018.1445836 · Cited by 10
Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding After Percutaneous Coronary Intervention via the Femoral Approach: Development and Validation of a New Bleeding Risk Score
Mangiacapra, F., Ricottini, E., Barbato, E., Demartini, C., Peace, A., Patti, G., Vizzi, V., de Bruyne, B., Wijns, W., & Sciascio, G. D. (2015) · Circulation. Cardiovascular Interventions · doi:10.1161/circinterventions.114.002106 · Cited by 10
Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention.
Parodi, G., Bellandi, B., Comito, V., Capodanno, D., Valenti, R., Marcucci, R., Carrabba, N., Migliorini, A., Gensini, G., Abbate, R., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.002 · Cited by 10
“In our study, despite the use of a reduced prasugrel maintenance dose, a higher average residual platelet reactivity, and a lower proportion of subjects showing low residual platelet reactivity (a risk factor that has been associated with bleeding risk [18]), elderly patients experienced more bleeding events than non-…”
Background
The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders
Bernlochner, I., Byrne, R. A., Kastrati, A., & Sibbing, D. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.80 · Cited by 4
Self-citation
Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.
Price, M., & Barker, C. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.1 · Cited by 10
PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease
Li, K.-C., Yu, S.-H., & Zhuge, B.-Z. (2017) · Medicine · doi:10.1097/md.0000000000007566 · Cited by 9
Diagnosis and Management of High Platelet Reactivity on Treatment with Clopidogrel
Cattaneo, M. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1326785 · Cited by 9
Intensified Antiplatelet Treatment Reduces Major Cardiac Events in Patients with Clopidogrel Low Response
Xu, L., Hu, X., Zhang, S., Li, J., Zhu, H., Xu, K., Chen, J., & Li, C. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.179786 · Cited by 7
“CLR is an independent risk factor for adverse clinical outcomes.[3,23,24] Theoretically, any intensified antiplatelet therapy that improves the platelet response should improve the patient’s clinical outcome.”
Background
Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel
Alfredsson, J., Lindahl, T. L., Gustafsson, K. M., Janzon, M., Jonasson, L., Logander, E., Nilsson, L. E., & Swahn, E. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.05.021 · Cited by 11
“[24] However, and in spite of a similar rate of HRPR, we found a very low rate of ischemic events.”
Result
II. Looking into the future of platelet transfusion in the presence of P2Y(12) inhibitors.
Tanaka, K., & Subramaniam, K. (2014) · British Journal of Anaesthesia · doi:10.1093/bja/aet584 · Cited by 8
Antiplatelet Agents
Gresele, P., & Page, C. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-29423-5 · Cited by 8
Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects
Chandiramani, R., Spirito, A., Johnson, J. W., Mehta, A., Vogel, B., FAILLACE, R. T., & Mehran, R. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2201437 · Cited by 8
“Despite these interesting observations, studies evaluating the implementation of platelet function testing (PFT) in clinical practice were largely unsuccessful [103,105,106] (Figure 3).”
Background
Sex differences in platelet reactivity in patients with myocardial infarction treated with triple antiplatelet therapy - results from assessing platelet activity in coronary heart disease (APACHE)
Holm, A., Swahn, E., Lawesson, S., Gustafsson, K., Janzon, M., Jonasson, L., Lindahl, T., & Alfredsson, J. (2020) · Platelets · doi:10.1080/09537104.2020.1771550 · Cited by 7
“sis post-PCI [41], whereas LRPR has been associated with an increased risk of bleeding [26].”
Background
Monitoring platelet function: what have we learned from randomized clinical trials?
Deharo, P., & Cuisset, T. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.10.10 · Cited by 8
“Strategies to target a therapeutic window for antiplatelet therapy, with intermediate degree of platelet inhibition (non-HTPR and non-LTPR), that would allow prevention of both ischemic and bleeding events, have been developed (38,39).”
Background
The role of platelet reactivity assessment in dual antiplatelet prophylaxis after transcatheter aortic valve implantation.
Czerwińska-Jelonkiewicz, K., Witkowski, A., Dąbrowski, M., Piotrowski, W., Hryniewiecki, T., & Stępińska, J. (2017) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2017.06.002 · Cited by 7
Temporal Changes in Platelet Response in Acute Coronary Syndrome Patients With Prasugrel and Clopidogrel After Stent Implantation
Tello‐Montoliu, A., Rivera, J., Hernández, D., Nicolas-Silvente, A. I., Jover, E., Rodríguez, A. I. E., Quintana, M., Romero, A., Orenes‐Piñero, E., Rivera‐Caravaca, J. M., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0471 · Cited by 7
Antiplatelet strategies in elderly people: still a long way to go
Sibbing, D., & Maßberg, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31387-3 · Cited by 7
Self-citation
Prognostic Role of Platelet Reactivity in Patients With Acute Coronary Syndromes
Cavallari, I., Nusca, A., Ricottini, E., & Sciascio, G. D. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000034 · Cited by 7
Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations
Karathanos, A., & Geisler, T. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0022-y · Cited by 6
“Other populations that could benefit from platelet function monitoring are elderly patients which have been reported to present a high rate of HPR [128] and in general individuals who are at a high risk of bleeding but at the same time at an increased risk of thrombosis [129, 130].”
Background
Utility of Platelet Function Testing in Cardiac Surgery in 2021
Görlinger, K., & Gandhi, A. (2021) · Journal of Cardiac Critical Care TSS · doi:10.1055/s-0041-1732839 · Cited by 6
The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention.
Jin, L.-J., Yu, H.-M., Dong, T.-M., Zhang, B., Yan, H., Liao, H.-T., & Zou, X. (2017) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2016.05.113 · Cited by 6
“[6,26,27] defined an optimal therapeutic window for P2Y12 receptor inhibition of 189-467 aggregation units min using a multiplate analyser, which supports defining approximately one-third of patients as patients at risk of bleeding.”
Method
Clinical Impact of Genetically Determined Platelet Reactivity
Laine, M., Arméro, S., Peyrol, M., Sbragia, P., Thuny, F., Paganelli, F., & Bonello, L. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9421-4 · Cited by 6
Entfernung eines Periduralkatheters unter dualer Antiplättchentherapie nach akutem Koronarsyndrom
Limper, U., & Lynch, J. (2012) · Der Anaesthesist · doi:10.1007/s00101-012-2067-4 · Cited by 6
Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?
Aradi, D., & Komócsi, A. (2012) · Platelets · doi:10.3109/09537104.2011.610475 · Cited by 6
“[42] have demonstrated the presence of a therapeutic window after thienopyridine administration by the VerifyNow (86-238 PRU) and Multiplate (19-47 U) assays, respectively.”
Method
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock
Orban, M., Byrne, R., Hausleiter, J., Laugwitz, K., & Sibbing, D. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-04-0267 · Cited by 6
“Peri-procedural assessment of P2Y12-mediated platelet inhibition due to thienopyridine treatment has been shown to be highly predictive for early thrombotic events after the procedure including the occurrence of stent thrombosis (1).”
BackgroundMethodInfluentialSelf-citation
De-Escalation of Treatment With Oral P2Y12 Receptor Inhibitors: Current Status and Perspectives
Alexopoulos, D., Lianos, I., Vlachakis, P., Sfantou, D., Dragona, V.-M., & Varlamos, C. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418823724 · Cited by 5
Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction
Alfredsson, J., Swahn, E., Gustafsson, K. M., Janzon, M., Jonasson, L., Logander, E., Nilsson, L. E., & Lindahl, T. L. (2018) · Platelets · doi:10.1080/09537104.2018.1479519 · Cited by 10
Prise en charge du risque hémorragique associé aux agents antiplaquettaires
Martin, A., Houssany-Pissot, S., Zlotnik, D., Taylor, G., & Godiér, A. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.01.013 · Cited by 8
Gerinnungsdiagnostik und -therapie bei Leberinsuffizienz
Bienholz, A., Canbay, A., & Saner, F. (2016) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-015-0027-x · Cited by 5
Low On‐Treatment Platelet Reactivity Predicts Long‐Term Risk of Bleeding After Elective PCI
Čolić, M., Čalija, B., Milosavljevic, B., Grdinić, A., Angelkov, L., Sagić, D., Kružliak, P., Marinković, J., Babić, R., & Mrdović, I. (2015) · Journal of Interventional Cardiology · doi:10.1111/joic.12251 · Cited by 6
Platelet function testing to time surgery in patients on dual antiplatelet therapy?
Mahla, E., Raggam, R., & Toller, W. (2013) · Hämostaseologie · doi:10.5482/hamo-13-06-0032 · Cited by 5
“For example, the predictive cutoff for surgery-related bleeding of 31 U (comparing to 310 AU × min) as suggested in the former study (37) was substantially higher than a suggested cutoff of 188 AU x min for procedure-related bleeding in patients undergoing PCI (42, 43).”
Method
Large interventricular septal aneurysm with thrombo-embolism in a healthy woman.
Sy, A. M., & Sahni, G. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr087 · Cited by 5
High residual platelet reactivity on standard clopidogrel maintenance dose predicts increased responsiveness to the doublestandard dose in an assay-dependent manner
Oestreich, J., Steinhubl, S., Ferraris, S., & Akers, W. S. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-09-0603 · Cited by 5
Self-citation
Platelet phenotypes and practical aspects of platelet function testing in cardiology
Kobalava, Z. D., Pisaryuk, A. S., Андреевна, Ф. А., Tukhsanboev, E. S., Boldyreva, A. A., Lazutova, D. P., Meray, I. A., & Panteleev, M. A. (2023) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2023-2981 · Cited by 5
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Malik, A. H., Gupta, R., Chakraborty, S., Mahajan, P., Bandyopadhyay, D., Yandrapalli, S., Zaid, S., Sreenivasan, J., Chaturvedi, A., Mehta, S. S., et al. (2022) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2022.01.005 · Cited by 6
Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy
Gruttemeier, J., Cottin, Y., Yao, H., de Maistre, E., Maza, M., Bonello, L., Laine, M., Resseguier, N., Zeller, M., Camoin-Jau, L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081565 · Cited by 4
Microvesicles from patients with acute coronary syndrome enhance platelet aggregation
Kafian, S., Wallén, H., Samad, B., & Mobarrez, F. (2019) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2019.1663554 · Cited by 4
Impact of platelet reactivity on long-term prognosis in Korean patients receiving percutaneous coronary intervention
Lee, S. N., Moon, D., Min, K. S., Moon, K., & Yoo, K. (2019) · Platelets · doi:10.1080/09537104.2018.1562172 · Cited by 4
Traditional clinical risk factors predict clopidogrel hypo-responsiveness in unselected patients undergoing non-emergent percutaneous coronary intervention
Ratcovich, H., Holmvang, L., Johansson, P. I., & Dridi, N. (2015) · Platelets · doi:10.3109/09537104.2015.1029899 · Cited by 4
Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients
Freeman, P. M., Moschonas, K., Hinz, C., O’Donnell, V. B., Kinnaird, T. D., James, P. E., & Anderson, R. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.024 · Cited by 6
Impact of Tailored Anti-P2Y12 Therapies in Acute Coronary Syndromes
Stimpfle, F., & Geisler, T. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.19 · Cited by 5
Correlation between Frequency of Microembolic Signals and Efficacy of Antiplatelet Therapy in Symptomatic Carotid Disease
Kerasnoudis, A., Meves, S., Gold, R., & Krogias, C. (2013) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2012.00770.x · Cited by 4
Current Role of Platelet Function Testing in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting
Groß, L., & Sibbing, D. (2016) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2016.08.011 · Cited by 4
Self-citation
Optimizing selection of P2Y 12 inhibiting therapy: clopidogrel, prasugrel or ticagrelor
Galli, M., Simeone, B., Gragnano, F., D’Amario, D., Sarto, G., Frati, G., Greco, E., Calabrò, P., Sciarretta, S., Mehran, R., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2576607 · Cited by 3
“Achieving OPR is associated with the most favorable safety and efficacy profile, minimizing the likelihood of adverse outcomes (Figure 2) [16,29,101,105,106].”
An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention
Wang, J., Wang, J., Dong, Z., Ma, J., Teng, J., Wang, T., Zhang, X., Gu, Q., Ye, Z., Ullah, I., et al. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00323-5 · Cited by 3
Genetic testing to guide therapy? Not for ticagrelor!
Hengstenberg, C., & Kastrati, A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehv229 · Cited by 3
“A large variability in platelet reactivity is shown for clopidogrel, the most commonly used P2Y12 receptor antagonist, with a relevant impact on ischaemic but also bleeding complications.(1,2) The large variability of platelet response is mainly explained by the fact that clopidogrel is a pro-drug which needs two step…”
BackgroundSelf-citation
Perioperativer Umgang mit Thrombozytenaggregationshemmern
Wagner, J., Lock, J., Luber, V., Dietz, U., Lichthardt, S., Matthes, N., Krajinovic, K., Germer, C., Knop, S., & Wiegering, A. (2018) · Der Chirurg · doi:10.1007/s00104-017-0525-x · Cited by 3
Platelet Function Measurement in Elective Percutaneous Coronary Intervention Patients
Tantry, U. S., Jeong, Y., Navarese, E. P., & Gurbel, P. A. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.01.007 · Cited by 3
“A potential therapeutic window was first demonstrated with impedance aggregometry (8).”
Background
Whole Blood Assay: Thromboelastometry – Basics
Görlinger, K., Iqbal, J., Dirkmann, D., & Tanaka, K. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-56338-7_6 · Cited by 3
Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry
Kang, J., Park, S., Park, K. W., Joo, H. J., Chang, K., Park, Y., Song, Y. B., Ahn, S. G., Suh, J., Lee, S. Y., et al. (2025) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.125.015737 · Cited by 2
Modulation of Antiplatelet Therapy in PCI-Treated Patients
Sibbing, D. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.355 · Cited by 2
Self-citation
Time-dependent changes in P2Y12 reaction unit values for predicting the different types of cardiovascular events in patients with ischemic heart disease
Aizawa, T., Inoue, Y., Ito, S., Morimoto, S., Ogawa, K., Nagoshi, T., Minai, K., Ogawa, T., Kawai, M., & Yoshimura, M. (2023) · Heart and Vessels · doi:10.1007/s00380-023-02279-0 · Cited by 2
“In patients with ischemic heart disease, high treatment platelet reactivity (HPR) has been found to be significantly associated with cardiovascular events on P2Y12 inhibitor therapy [1, 2].”
Background
Platelet Function Testing and Genotyping for Tailoring Treatment in Complex PCI Patients
Μούλιας, Α., Papageorgiou, A., & Alexopoulos, D. K. (2021) · US Cardiology Review · doi:10.15420/usc.2020.33 · Cited by 1
“27 30 However, a PFT-guided de-escalation approach was found to be non-inferior for the primary endpoint of net clinical benefit (cardiovascular death, MI, stroke or bleeding grade ≥2 according to Bleeding Academic Research Consortium [BARC] criteria) compared with potent platelet inhibition for 12…”
Assessment of Steady-State Clopidogrel Reactivity by Using Platelet Reactivity Units
Rasool, S., Khalaf, H., Almeman, A., & Alorainy, M. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000199 · Cited by 2
Clopidogrel Response Variability: Etiology and Clinical Relevance
Bonello, L., Gaubert, M., Laine, M., Barragan, P. T., Pinto, J., Iloud, A., Lemesle, G., Roch, A., Dignat‐George, F., Paganelli, F. F., et al. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0437-6 · Cited by 2
Gastrointestinale Blutungen beim kardiologischen Patienten
Braun, G., & Messmann, H. (2013) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-013-0257-8 · Cited by 2
Impact of high on-treatment platelet reactivity on long-term clinical events in AMI patients: a fact or mirage?
Jeong, Y., Ahn, J., & Shin, E. (2017) · Anatolian journal of cardiology · doi:10.14744/anatoljcardiol.2016.22626 · Cited by 2
“, 5-year) adverse events in AMI patients using the readily available Multiplate® analyzer (8).”
Method
The role of laboratory monitoring in antiplatelet therapy.
Cattaneo, M. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-29423-5_19 · Cited by 2
“In contrast, only recently this important clinical issue has started to be addressed for some tests of platelet function used for tailoring clopidogrel therapy (Bonello et al. 2010; Campo et al. 2011; Sibbing et al. 2010), and the cut-off values for both the risk of thrombosis (see later) and the risk of bleeding are…”
Background
Antiplatelet therapy in high-bleeding risk patients with acute coronary syndrome: pharmacogenomics in the era of precision medicine
Michailidis, N., Pallikarou, M., Manolopoulos, V. G., Moschovidis, V., Ziakas, A., Ragia, G., & Kassimis, G. (2026) · Pharmacogenomics · doi:10.1080/14622416.2026.2648609 · Cited by 1
Rotational Thromboelastometry (ROTEM®)
Görlinger, K., Dirkmann, D., & Hanke, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-53606-0_18 · Cited by 3
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients
Kukuła, K., Kłopotowski, M. M., Kunicki, P. K., Jamiołkowski, J., Dębski, A., Bekta, P., Chmielak, Z., & Witkowski, A. (2016) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000614 · Cited by 3
Platelet reactivity and antiplatelet management in diabetic patients with coronary artery disease
Proscia, C., Nusca, A., Mega, S., Melfi, R., & Sciascio, G. D. (2015) · Interventional Cardiology · doi:10.2217/ica.15.9 · Cited by 1
Tailoring of antiplatelet therapy in a patient with bleeding and PCI: a double-edged sword?
Skorić, B., Samardžić, J., Planinc, I., Krpan, M., Strozzi, M., & Miličić, D. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.271 · Cited by 1
Assessing post-treatment platelet reactivity: a focus on patient selection and setting
Laine, M., Frère, C., Ronsin, O., Gaubert, M., Toesca, R., Bessereau, J., Michelet, P., Gramond, C., Helal, O., Paganelli, F. F., et al. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.820440 · Cited by 1
Bleeding and Thrombosis Risk Matters
Sibbing, D., Groß, L., Orban, M., & Maßberg, S. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.06.002 · Cited by 1
Self-citation
Biological efficacy and clinical safety of a second 600 mg loading dose of clopidogrel in elderly patients with high on-treatment platelet reactivity: a pilot study.
Laine, M., Paganelli, F., George, F., Camoin-Jau, L., & Bonello, L. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.08.019 · Cited by 1
Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
Sciascio, G. D., & Mangiacapra, F. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.033 · Cited by 1
Panta rhei
Görlinger, K. (2012) · Der Anaesthesist · doi:10.1007/s00101-012-2051-z · Cited by 1
Bedside Monitoring of Antiplatelet Therapy for Coronary Stenting
Montalescot, G., Vicaut, É., & Collet, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300053 · Cited by 15
Ticagrelor versus clopidogrel in STEMI post-PCI: A mixed-design meta-analysis of efficacy and safety
Shahid, M. M., Sajjad, M. H., Patel, S. K. P., Tarar, M. F., Rasheed, M. A., Jaffar, M. S., Rana, M. A., Abbas, M. H., Rasheed, A. B., Shahid, M., et al. (2026) · Medicine · doi:10.1097/md.0000000000049923
“[28] The moderate heterogeneity ( I 2 = 27”
Influential
Ex Vivo Thrombocyte Function and Its Response to NO/Sildenafil in Patients Undergoing Hemodialysis
Bonell, V., Schmaderer, C., Lorenz, G., Günthner, R., Angermann, S., Bachmann, Q., Küchle, C., Renders, L., Heemann, U. W., Kessler, T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145156
“To minimize confounding, we excluded participants with potential causes of platelet dysfunction such as hematological disorders, liver cirrhosis, active infections, or ADP receptor antagonist therapy [33].”
Tratamientos antiplaquetarios
Gaussem, P., Jourdi, G., & Ajzenberg, N. (2022) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(15)70944-x
Traitements antiplaquettaires
Gaussem, P., Jourdi, G., & Ajzenberg, N. (2022) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(22)44393-6
Therapeutic Window of P2Y12 Inhibition: Should the Current Limits Be Modified?
Lozano, Í., de Prado, A. P., Hernández, J. M. D. L. T., Blanco, B. G. D., & Rumoroso, J. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.09.025
Reply: Therapeutic Window of P2Y12 Inhibition: Should the Current Limits Be Modified?
Sibbing, D., & Angiolillo, D. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.10.015
Self-citation
[Duration and Timing of Initiation of Therapy With Platelet P2Y12 Inhibitors in the Treatment of Patients With Acute Coronary Syndrome].
Shalaev, S., & Safiullina, Z. (2018) · Kardiologiia · doi:10.18087/cardio.2018.3.10099
“образованием, так и с кровотечениями [6].”
In dubious battle: bleeding versus ischemic events
Bonello, L., Laine, M., & Frère, C. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1383-y
Traitements antiplaquettaires
Gaussem, P., & Ajzenberg, N. (2016) · International Conference on Embedded and Multimedia Computing · doi:10.1016/s1877-7848(15)77112-1
Traitements antiplaquettaires
Gaussem, P., & Ajzenberg, N. (2015) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(14)56285-0
VerifyNow P2Y12 and Plateletworks Assays
Price, M. J., Breet, N. J., & ten Berg, J. M. (2014) · Wiley eBooks · doi:10.1002/9781118493984.ch9
Vasodilator‐Stimulated Phosphoprotein (VASP) Assay
Laine, M., Paganelli, F., & Bonello, L. (2014) · doi:10.1002/9781118493984.ch8
Pharmacodynamics- and Pharmacogenetics-Guided Antiplatelet Therapy
Tello-Montoliu, A., & Angiolillo, D. (2014) · doi:10.1201/b15465-24
Ticagrelor in Acute Coronary Syndromes
Howard, C. (2015) · doi:10.26686/wgtn.17014211
“111 5.5 CONCLUSION .......................................................................................................................... 112 REFERENCES ................................................................................................................................ 113 x Abbreviations ACS- acute co…”
MethodInfluential
Residual platelet reactivity in atherosclerosis and its impact on patient outcomes
Johnston, L. R. (2014) · doi:10.26686/wgtn.17007475.v1
“Maori and Pacific Islanders had higher residual platelet reactivity (50 AU (35-70) versus 38 AU (250-570), p = 0.”
Background
Clinical significance of monitoring tests for anti-platelet drugs
Hato, T. (2012) · doi:10.2491/jjsth.23.352
Perioperative Considerations and Management in Patients with Intravascular Stents
Lynch, I. P., Emmert, D. A., & Wall, M. (2011) · doi:10.1016/j.aan.2011.07.003

Authors: Sibbing, D., Steinhubl, S. R., Schulz, S., Schömig, A., & Kastrati, A.
Corresponding author: Sibbing, Dirk
ORCID: Sibbing, Dirk
Steinhubl, Steven R.
Schulz, Stefanie
Kastrati, Adnan
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2010-07
Volume: 56
Issue: 4
Pages: 317-318
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2010.03.048
OpenAlex: W81845835
Cited by: 208
References: 0
Citations by year: 2026: 2 · 2025: 5 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 12 · 2018: 7 · 2017: 10 · 2016: 15 · 2015: 23 · 2014: 20 · 2013: 33 · 2012: 32
FWCI: 20.63
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1111 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: platelet aggregation, clopidogrel, stent thrombosis, hemorrhage, clopidogrel resistance, interindividual variability, antiplatelet therapy, percutaneous coronary intervention
MeSH terms: Clopidogrel, Coronary Thrombosis, Hemorrhage, Humans, Platelet Aggregation, Ticlopidine, Time Factors, Receptors, Purinergic P2, Drug-Eluting Stents, Purinergic P2 Receptor Antagonists, Receptors, Purinergic P2Y12

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks